Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

Core Viewpoint - Krystal Biotech, Inc. is set to report its first quarter 2025 financial results on May 6, 2025, and will host a conference call to discuss these results and provide a business update [1]. Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing genetic medicines for diseases with high unmet medical needs [3]. - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy approved by the FDA for treating dystrophic epidermolysis bullosa [3]. - The company is advancing a robust pipeline of investigational genetic medicines across various fields, including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]. - Krystal Biotech is headquartered in Pittsburgh, Pennsylvania [3].